Moxifloxacin prophylaxis in neutropenic patients

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 891-894

  von Baum, H ^a   Sigge, A ^a   Bommer, M ^a   Kern, W V ^b   Marre, R ^a   Dohner H ^a   Kern, P ^a   Reuter, Stefan ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anaerobes; Clostridium difficile; Fluoroquinolones; Levofloxacin; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM;

ANAEROBIC BACTERIUM; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; SURVIVAL RATE;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; AZA COMPOUNDS; BACTEREMIA; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; NEUTROPENIA; OFLOXACIN; QUINOLINES;

EID: 33748687964     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl320     Document Type: Article

References (10)

1. Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-87.
2. Reuter S, Kern WV, Sigge A et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40: 1087-93.
3. Gafter-Gvili A, Fraser A, Paul M et al. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95.
4. Kern WV, Klose K, Jellen-Ritter AS et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-8.
5. Ackermann G, Schaumann R, Pless B et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32.
6. Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598-607.
7. Clasener HA, Vollaard EJ, van Saene HK. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis 1987; 9: 295-328.
8. Paterson DL. 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4: S341-5.
9. Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: Association with gatifloxacin use. Clin Infect Dis 2004; 38: 640-5.
10. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.